The PennZone

  • Home
  • Non-profit
  • Health
  • Books
  • Entertainment
  • Business
  • Legal
  • Marketing
  • Financial

Congruence Therapeutics Announces Poster Presentation on Discovery of Novel GCase Correctors for Parkinson's Disease with GBA1 Mutations at the 2024 International Congress of Parkinson's Disease and Movement Disorders Meeting
The PennZone/10283317

Trending...
  • Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
  • UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
  • Woodside Village Joins Corner Property Management Following CMP Acquisition
~ Congruence Therapeutics, a biotechnology company focused on developing small molecule correctors to rescue aberrant protein function, has announced their participation in the International Congress of Parkinson's Disease and Movement Disorders 2024 Meeting. The event will take place from September 27th to October 1st, 2024 in Philadelphia, PA.

The company's Chief Scientific Officer, Sharath Hegde, Ph.D., shared that mutations of the GBA1 gene are considered the most significant genetic risk factor for Parkinson's Disease. Congruence is dedicated to addressing this issue by utilizing their proprietary platform Revenir™ to discover potent and brain-penetrant allosteric GCase correctors. These molecules have shown promising results in preclinical studies.

More on The PennZone
  • Education Through Music-LA Honors Grammy-Winning Pitch Perfect Music Supervisors Julianne Jordan & Julia Michels, Educator Anthony "Tony" White
  • TOKSTAR Welcomes NBA 2K Star Young Wayne
  • Matt Zavala of Zavala Law, PC Elected to Ventura County Bar Association Board of Directors
  • Prolific Press Opens Full-Length Book Submissions for Poetry, Fiction and Non-Fiction
  • Clear Path Landscaping Announces Commercial and Residential Snow Removal for 2026-27 Season

At the conference, Congruence will present a poster titled "Identification of Allosteric GCase Correctors using Revenir™ for the treatment of GBA1-Parkinson's Disease." The abstract number for this presentation is 791 and it is scheduled for Sunday, September 29th from 1-3PM. Jeremy Dupaul-Chicoine, Associate Director of Biology at Congruence Therapeutics, will be the presenting author.

The company's efforts to develop effective treatments for GBA1-Parkinson's Disease have yielded positive results and they continue to optimize their chemical leads in hopes of discovering potential clinical candidates. This presentation at the International Congress of Parkinson's Disease and Movement Disorders serves as a testament to Congruence Therapeutics' dedication to improving the lives of those affected by this debilitating disease.
Filed Under: Business

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • PinnacleQM launches new enterprise website to help Australian organisations deliver more with confidence
  • 33,714 US social services nonprofits and the funding calls still open to them
  • Loud! OOH Launches UK's First Free Planning Tool for UK Outdoor Advertising Budgets
  • Local Man Needs Assistance with Housing
  • Carew Papritz Revisits His Reading Eagle Op-Ed on Dolly Parton Ahead of CMA Awards Tribute
  • Boston Industrial Solutions Introduces the New Volta® M100 Pad Printing Machine
  • Not a Black Box Launches TalentOS, the First Talent Harness Operating System
  • A Diwali Celebration with Heritage at South Brunswick Residents & American Properties
  • Law Offices of Larry E. Bray, P.A. Wins Fourth District Appeal Clarifying Limits of Florida's Offer of Judgment Statute
  • Holiday Magic Returns to Downtown Downers Grove November 27-29
  • ET&T Named Philadelphia Business Journal Family-Owned Business Awards Honoree
  • What If the Greatest Gift This Holiday Season Came in a Dream of Your Loved One in Spirit?
  • 6,238 executives took new roles at US nonprofits from June to October 2026
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis
  • LGF Lab Gas Flow Launches Fully Automatic Laboratory Gas Changeover Manifold System with Ultra High Purity Gas Regulator Valve
  • Woodside Village Joins Corner Property Management Following CMP Acquisition
  • 20-Year Crash Cost of Signalized RC3 Cloverleaf Could Exceed $25 Million
  • Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
  • Inaugural 12 Trees of Christmas gala raises $525,000 for DMG research and family support
  • BitTitan Expands MigrationWiz with SharePoint Sites Migration and Simplified Collaboration Licensing

Popular on PennZone

  • ALight Technology And Services Limited Advances Through Peachscore + Dealum Accelerator and Join LvlUp Labs - 184
  • Hunter's Garage Teams Up With The Small Batch for a Free Thanksgiving Meal - 177
  • WebDrafter Welcomes Dreamwork Exteriors as a New Marketing Client - 143
  • Conservative Latinos for PA PAC Endorses Stacy Garrity for Governor: "Pennsylvania's Latino Families Need a Leader Who Delivers" - 112
  • Communities In Schools of Eastern Pennsylvania Honors United Way and Local Leaders - 103
  • Charlie Shaw and Patrick Carragher win SEO Agency of the Year 2026
  • RAS AP Consulting Advances 1099 Education and Readiness Initiative Through IFOL Training and Finance Technology Showcase
  • Alan Hamilton of Shiver Hamilton Campbell Inducted as a Fellow of the American College of Trial Lawyers
  • Pastor Carlton L. Aiken Sr. Celebrates 55 Years with "Sermonic Selections"
  • No Bounds Digital Acquires Draidel's HubSpot Agency Business, Expanding Reach and Capabilities

Similar on PennZone

  • Scott Glickson Joins STS Capital Partners as Managing Director
  • BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Dallas–Fort Worth
  • Loud! OOH Launches UK's First Free Planning Tool for UK Outdoor Advertising Budgets
  • Boston Industrial Solutions Introduces the New Volta® M100 Pad Printing Machine
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis
  • Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
  • Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us